HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

Although it is known that molecules with anti-HIV activity circulate in human blood, their identification has been hampered by difficulties in the purification and characterization of such compounds.

Interestingly, the anti-HIV-1 targets of triterpene analogs can vary depending on the side chain modification position. C-28 modified betulinic acid analogs are potent HIV entry inhibitors, while ...

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile ...